Cristiano de Sa Fernandes

Cristiano de Sa Fernandes

Auto-generated profile, based on publicly available information

Cristiano de Sa Fernandes

Center for Cancer Research & Comprehensive Cancer Center (CCC), Medical University of Vienna, Vienna, Austria

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 May 2025 in EMBO Molecular Medicine
Verified
Journal Article
Open access
DKDana Krauß
Dana Krauß
Veronica Moreno-ViedmaVeronica Moreno-Viedma
Veronica Moreno-Viedma
EAEmi Adachi-Fernandez
Emi Adachi-Fernandez
CFCristiano de Sá Fernandes
Cristiano de Sá Fernandes
JGJakob-Wendelin Genger
Jakob-Wendelin Genger
MSMaria Sibilia
Maria Sibilia
Inhibition of the epidermal growth factor receptor (EGFR) shows clinical benefit in metastatic colorectal cancer (CRC) patients, but KRAS-mutations are known to confer resistance. However, recent reports highlight EGFR as a crucial target to be co-inhibited with RAS inhibitors for effective treatment of KRAS mutant CRC. Here, we investigated the tumor cell-intrinsic contribution of EGFR in KRAS G12D tumors by establishing murine CRC organoids with key CRC mutations (KRAS, APC, TP53) and inducible EGFR deletion. Metabolomic, transcriptomic, and scRNA-analyses revealed that EGFR deletion in KRAS-mutant organoids reduced their phenotypic heterogeneity and activated a distinct cancer-stem-cell/WNT signature associated with reduced cell size and downregulation of major signaling cascades like MAPK, PI3K, and ErbB. This was accompanied by metabolic rewiring with a decrease in glycolytic routing and increased anaplerotic glutaminolysis. Mechanistically, following EGFR loss, Smoc2 was identified as a key upregulated target mediating these phenotypes that could be rescued upon additional Smoc2 deletion. Validation in patient-datasets revealed that the identified signature is associated with better overall survival of RAS mutant CRC patients possibly allowing to predict therapy responses in patients.

24 September 2025 in Cancer Research
Verified
Journal Article
Open access
BMBernadette Mödl
Bernadette Mödl
DZDaniela Zwolanek
Daniela Zwolanek
KSKatharina Schwertner
Katharina Schwertner
DKDana Krauß
Dana Krauß
SMStefan Moritsch
Stefan Moritsch
RERobert Eferl
Robert Eferl
Colorectal cancer liver metastasis (CRLM) is a major clinical problem. The regulators of immunosurveillance of CRLM could hold potential for developing therapeutic strategies to prevent or treat metastasis. In this study, using a murine colorectal cancer organoid-based transplantation model, we identified TYK2 as a key factor controlling CRLM. Evaluation of the effects of Tyk2 deletion in different subsets of immune cells and in colorectal cancer cells demonstrated that TYK2 was not required in cancer cells, macrophages, NK cells, T cells, or Kupffer cells. Instead, TYK2 controlled CRLM via a dendritic cell–dependent mechanism that relied on MHC-I–mediated cross-presentation of antigens to CD8+ T cells. Analysis of single-cell RNA sequencing data from primary colorectal cancer and CRLM revealed that TYK2 was predominantly expressed in a dendritic cell population destined to present antigens in tumor-draining lymph nodes. Treatment with the TYK2 inhibitor deucravacitinib, which is approved by the FDA for treating plaque psoriasis and is under clinical investigation for other autoimmune diseases, promoted CRLM. Together, these data demonstrate that TYK2 controls CRLM immunosurveillance, which should be carefully considered when treating patients with TYK2 inhibitors. Significance: TYK2 restricts the metastasis of colorectal tumors to the liver by supporting dendritic cell-dependent induction of antitumor CD8+ T cells, which could impact the use of TYK2 inhibitors in patients.

2 January 2026
Verified
Other
Open access
BMBernadette Mödl
Bernadette Mödl
DZDaniela Zwolanek
Daniela Zwolanek
KSKatharina Schwertner
Katharina Schwertner
DKDana Krauß
Dana Krauß
SMStefan Moritsch
Stefan Moritsch
RERobert Eferl
Robert Eferl
MRNA expression of cytokines, chemokines, costimulatory molecules and immune checkpoints in healthy and metastases-bearing livers of TYK2flox/flox and TYK2Δhem host mice

2 January 2026
Verified
Other
Open access
BMBernadette Mödl
Bernadette Mödl
DZDaniela Zwolanek
Daniela Zwolanek
KSKatharina Schwertner
Katharina Schwertner
DKDana Krauß
Dana Krauß
SMStefan Moritsch
Stefan Moritsch
RERobert Eferl
Robert Eferl
Inverse correlation between metastatic load and immune infiltration

2 January 2026
Verified
Other
Open access
BMBernadette Mödl
Bernadette Mödl
DZDaniela Zwolanek
Daniela Zwolanek
KSKatharina Schwertner
Katharina Schwertner
DKDana Krauß
Dana Krauß
SMStefan Moritsch
Stefan Moritsch
RERobert Eferl
Robert Eferl
Colorectal cancer liver metastasis (CRLM) is a major clinical problem. The regulators of immunosurveillance of CRLM could hold potential for developing therapeutic strategies to prevent or treat metastasis. In this study, using a murine colorectal cancer organoid-based transplantation model, we identified TYK2 as a key factor controlling CRLM. Evaluation of the effects of Tyk2 deletion in different subsets of immune cells and in colorectal cancer cells demonstrated that TYK2 was not required in cancer cells, macrophages, NK cells, T cells, or Kupffer cells. Instead, TYK2 controlled CRLM via a dendritic cell–dependent mechanism that relied on MHC-I–mediated cross-presentation of antigens to CD8+ T cells. Analysis of single-cell RNA sequencing data from primary colorectal cancer and CRLM revealed that TYK2 was predominantly expressed in a dendritic cell population destined to present antigens in tumor-draining lymph nodes. Treatment with the TYK2 inhibitor deucravacitinib, which is approved by the FDA for treating plaque psoriasis and is under clinical investigation for other autoimmune diseases, promoted CRLM. Together, these data demonstrate that TYK2 controls CRLM immunosurveillance, which should be carefully considered when treating patients with TYK2 inhibitors.Significance:TYK2 restricts the metastasis of colorectal tumors to the liver by supporting dendritic cell-dependent induction of antitumor CD8+ T cells, which could impact the use of TYK2 inhibitors in patients.

2 January 2026
Verified
Other
Open access
BMBernadette Mödl
Bernadette Mödl
DZDaniela Zwolanek
Daniela Zwolanek
KSKatharina Schwertner
Katharina Schwertner
DKDana Krauß
Dana Krauß
SMStefan Moritsch
Stefan Moritsch
RERobert Eferl
Robert Eferl
Evaluation of TYK2 deletion in conditional mouse models